BioNTech SE

+++ 𝗢𝘂𝗿 𝗺𝗥𝗡𝗔 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗖𝗲𝗻𝘁𝗲𝗿 𝗶𝗻 𝗠𝗲𝗹𝗯𝗼𝘂𝗿𝗻𝗲 𝗵𝗮𝘀 𝗼𝗽𝗲𝗻𝗲𝗱 +++ 🚀 We are excited to contribute to strengthen one of the leading life sciences hubs in the Asia Pacific region with our mRNA Innovation Center in Melbourne. Based on our strategic partnership with the State of Victoria, we aim to support the development of the local mRNA ecosystem by working with researchers, start-ups and other third parties, helping them advance their mRNA research and provide scientific mentoring for a potential transition into preclinical and clinical development.    🔬 Our team of first movers and pioneering scientists has a proven track record of translating academic research into clinical development: Our experts have developed a clinical pipeline of innovative investigational immunotherapies and vaccines to address cancer, infectious diseases, and other serious diseases. We are looking forward to supporting the State of Victoria’s mRNA ecosystem with our expertise.    💡 Curious about other things we're currently working on in Australia with mRNA Victoria and La Trobe University?     Learn more: https://lnkd.in/eNCyGEUb     #BioNTech #innovation #technology #startup #Australia #Melbourne #mRNA #oncology      📸: La Trobe University 

+++ 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐍𝐞𝐰𝐬: 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐂𝐇𝐌𝐏 𝐨𝐩𝐢𝐧𝐢𝐨𝐧 𝐟𝐨𝐫 𝐨𝐮𝐫 𝐚𝐝𝐚𝐩𝐭𝐞𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞+++ As we remain committed to providing COVID-19 vaccines that are matched to relevant circulating variants or sublineages, we are happy to announce that we and our partner Pfizer have received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for our monovalent Omicron JN.1-adapted #COVID19 Vaccine in the European Union.    The European Commission (EC) will review the CHMP’s recommendation and is expected to make a final decision soon. Following the EC decision, the updated vaccine will be available to ship to applicable EU member states immediately. 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞: https://lnkd.in/e9sV7Qfn

+++ 𝐌𝐞𝐞𝐭 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬: 𝐒𝐞𝐛𝐚𝐬𝐭𝐢𝐚𝐧 𝐇𝐲𝐦𝐬𝐨𝐧 +++ “Diversity and inclusion really mean to me not just tolerating the differences between each other but embracing them. We don't have to change who we are on the outside just to be accepted at work,” says Sebastian Hymson (he/him/his). Working at BioNTech as a scientist based in the U.S., he is also part of our employee resource group to promote a diverse and inclusive workplace. #𝐓𝐞𝐚𝐦𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐢𝐬 𝐚𝐥𝐥-𝐞𝐦𝐛𝐫𝐚𝐜𝐢𝐧𝐠 With his engagement, Sebastian makes an important contribution to our culture - and to the realization of our vision: We value and encourage diversity and firmly believe that it fosters innovation and helps us gain new perspectives. We are convinced that our differences make us stronger and more successful in our mission to develop pioneering immunotherapies to fight cancer and other serious diseases. Become part of #TeamBioNTech and add your perspective. 𝑳𝒆𝒂𝒓𝒏 𝒎𝒐𝒓𝒆 𝒂𝒃𝒐𝒖𝒕 𝒐𝒑𝒆𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒔: https://lnkd.in/dFN2BQPq

+++ 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐍𝐞𝐰𝐬: 𝐅𝐃𝐀 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤 𝐝𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐁𝐍𝐓𝟑𝟐𝟰 +++ The U.S. FDA just granted Fast Track designation for our antibody-drug conjugate (ADC) candidate BNT324/DB-1311, which we jointly develop with our partner Duality Biologics, for the treatment of patients with advanced/unresectable, or metastatic castration–resistant #ProstateCancer. With this decision, all three clinical stage antibody-drug conjugate candidates in our strategic collaboration with our partner have received FDA Fast Track designation supporting the potential of our antibody-drug conjugate technology. This designation contributes to the progress of our oncology pipeline. Our aim is to address the continuum of cancer treatments from early disease stages to late-stage metastatic disease. 𝙈𝙚𝙙𝙞𝙘𝙖𝙡 𝙉𝙚𝙚𝙙: Prostate cancer is the second leading cause of cancer-related death among men worldwide and is often diagnosed at advanced disease stages. [1] Patients with metastatic castration–resistant prostate cancer, an advanced form of prostate cancer, have a 5-year survival rate of only around 36%. [2] 𝘼𝙗𝙤𝙪𝙩 𝙖𝙣𝙩𝙞𝙗𝙤𝙙𝙮-𝙙𝙧𝙪𝙜 𝙘𝙤𝙣𝙟𝙪𝙜𝙖𝙩𝙚𝙨: Antibody-drug conjugates are a targeted type of treatment which combines two treatment approaches: the selectivity of antibodies and the potent cell-killing properties of chemotherapy or other anti-cancer drugs, thereby aiming to better identify and target specific types of cancer cells. 𝙍𝙚𝙖𝙙 𝙢𝙤𝙧𝙚: https://lnkd.in/dSbkbKnN   𝙍𝙚𝙛𝙚𝙧𝙚𝙣𝙘𝙚𝙨: [1] Cancer TODAY. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Available at: https://gco.iarc.who.int (last access: 20.06.2024). [2] SEER*Explorer: An interactive website for SEER cancer statistics. Cancer Stat Facts: Prostate Cancer. 2024 Apr 17. Available at: https://lnkd.in/gMgRyjf (last access: 20.06.2024).

+++ 𝐌𝐞𝐞𝐭 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐩𝐢𝐨𝐧𝐞𝐞𝐫𝐬: 𝐌𝐞𝐫𝐢𝐞𝐦 𝐂𝐡𝐞𝐧𝐢𝐧𝐢 +++ “We all have one big goal in mind. We're working towards it. It's fighting cancer,” says Meriem Chenini. As part of our BioNTech Site Services team, Meriem works to provide a working environment for her colleagues to help realize this vision – in Mainz, but also at all other BioNTech sites around the world. #𝐓𝐞𝐚𝐦𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 – 𝐄𝐯𝐞𝐫𝐲𝐨𝐧𝐞 𝐜𝐨𝐮𝐧𝐭𝐬 Meriem’s work emphasizes the importance of every single member of #TeamBioNTech. Without the contribution of our colleagues in enabling functions, it would not be possible to develop pioneering immunotherapies aiming to fight cancer and other serious diseases. We can only achieve this if our colleagues across all departments give their best. We are looking for colleagues to jointly work with us on realizing a vision of a healthier tomorrow. 𝑬𝒙𝒑𝒍𝒐𝒓𝒆 𝒐𝒑𝒆𝒏 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒔 𝒂𝒕 𝒐𝒖𝒓 𝒇𝒂𝒄𝒊𝒍𝒊𝒕𝒚 𝒇𝒐𝒓 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒊𝒏𝒈 𝒐𝒖𝒓 𝒊𝒏𝒗𝒆𝒔𝒕𝒊𝒈𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒑𝒆𝒓𝒔𝒐𝒏𝒂𝒍𝒊𝒛𝒆𝒅 𝒄𝒂𝒏𝒄𝒆𝒓 𝒗𝒂𝒄𝒄𝒊𝒏𝒆𝒔 𝒊𝒏 𝑴𝒂𝒊𝒏𝒛: https://lnkd.in/dg49yN5S

🔍 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡’𝐬 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐚𝐭 𝐨𝐮𝐫 𝐯𝐞𝐫𝐲 𝐟𝐢𝐫𝐬𝐭 #𝐀𝐒𝐂𝐎𝟐𝟎𝟐𝟒 𝐛𝐨𝐨𝐭𝐡 𝐢𝐧 𝐂𝐡𝐢𝐜𝐚𝐠𝐨! We are here to exchange with the community of experts working towards potential new therapies for patients with #cancer. For example, BioNTech's clinical pipeline features different therapeutic modalities including #mRNA, CAR-T, mono- and bispecific antibodies, and antibody-drug conjugates (ADCs). 𝐄𝐱𝐜𝐢𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐜𝐡𝐚𝐧𝐠𝐞? 𝐌𝐞𝐞𝐭 #𝐓𝐞𝐚𝐦𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐚𝐭 𝐛𝐨𝐨𝐭𝐡 # 𝟏𝟔𝟏𝟓𝟑. 📊 Get our clinical highlights to be presented at ASCO: https://lnkd.in/ePCjpgJu 📊 Explore Initial Phase 2 data for GEN1046/BNT311, a next-gen bispecific antibody candidate: https://lnkd.in/e7azDauj 👉𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞: https://lnkd.in/eEbKhHrf

++ 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡-𝐂𝐄𝐏𝐈 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐭𝐨 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 +++ Today we announced an expanded partnership with CEPI (Coalition for Epidemic Preparedness Innovations) to broaden the scope of our manufacturing facility in Africa. With this we also want to support the entire spectrum – from local research and clinical trials to commercial production.  🌍 𝐂𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐧𝐨𝐯𝐞𝐥 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: BioNTech and CEPI commit to enabling equitable access, including affordable pricing to select vaccines produced at BioNTech’s facility in Kigali, with priority access to African countries. 🛡 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐣𝐨𝐢𝐧𝐭𝐥𝐲 𝐨𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐩𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝𝐧𝐞𝐬𝐬: In the event of a disease outbreak, BioNTech would dedicate up to half of the facility’s manufacturing capacity to produce emergency response mRNA vaccines, subject to regulatory authorization.  🥼 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐢𝐧 𝐀𝐟𝐫𝐢𝐜𝐚: BioNTech will dedicate manufacturing capacities to third party projects aimed at enabling R&D activities for novel mRNA-based vaccine candidates against pathogens with epidemic or pandemic potential. We are thankful for the trust put in us by various partners and collaborators. Our joint efforts are aimed at supporting the African Union’s and Africa CDC's goal of producing 60 percent of total vaccine doses required on the continent by 2040. 𝑳𝒊𝒏𝒌 𝒕𝒐 𝒑𝒓𝒆𝒔𝒔 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 𝒂𝒏𝒅 𝒇𝒐𝒓𝒘𝒂𝒓𝒅-𝒍𝒐𝒐𝒌𝒊𝒏𝒈 𝒔𝒕𝒂𝒕𝒆𝒎𝒆𝒏𝒕𝒔: https://lnkd.in/evyfhEYs  

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐚𝐭 𝐀𝐒𝐂𝐎 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 𝟐𝟎𝟐𝟒 We are excited to present updates for selected programs of our immuno-oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago. This year’s presentations feature updates across all three key pillars of our diversified oncology pipeline, including novel #immunomodulators, targeted therapies such as CAR-T cell therapy candidates, and therapeutic #mRNA cancer vaccines.   Our aim with our modality-agnostic toolbox is to develop innovative treatment options across the continuum of #cancer disease and establish new treatment paradigms that have the potential to address the fundamental challenges of treating cancer with the aim to drive meaningful improvements in the long-term survival rates for patients. 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐚𝐭 #𝐀𝐒𝐂𝐎𝟐𝟒. 👇 𝑹𝒆𝒂𝒅 𝒎𝒐𝒓𝒆: https://lnkd.in/ePCjpgJu

+++ 𝗔𝗻𝗻𝘂𝗮𝗹 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 +++ We have just concluded our #AGM2024. All resolutions proposed on the agenda items put to the vote today at the AGM were approved by a large majority of the shareholders. “2023 was a year in which we made important progress in many areas: We maintained a leading position in the COVID-19 vaccine market, published encouraging data for candidates in our oncology pipeline and launched potentially registrational trials. Additionally, we have strengthened our organization in preparation for the next phase of growth, particularly with regards to our planned product launches in oncology,” said our CEO and Co-Founder Ugur Sahin. “We are convinced that our therapies under development, if approved, have the potential to complement established cancer treatment approaches in many areas in the future.” The detailed voting results for all agenda items can be viewed on our website under the following link: https://lnkd.in/eqczZUJ6 𝙇𝙞𝙣𝙠 𝙩𝙤 𝙥𝙧𝙚𝙨𝙨 𝙧𝙚𝙡𝙚𝙖𝙨𝙚 𝙖𝙣𝙙 𝙛𝙤𝙧𝙬𝙖𝙧𝙙-𝙡𝙤𝙤𝙠𝙞𝙣𝙜 𝙨𝙩𝙖𝙩𝙚𝙢𝙚𝙣𝙩𝙨: https://lnkd.in/eamehhH2 

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH